MedTrace Logo

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

NCT01720264 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).

Conditions

  • Acute Myeloid Leukemia
  • Acute Lymphoid Leukemia
  • Hematopoetic Myelodysplasia
  • Leukemia, Myelogenous, Chronic
  • Lymphoma, Non-Hodgkin

Interventions

DRUG

Sitagliptin

Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Sherif S. Farag

    lead OTHER

Principal Investigators

  • Sherif S Farag, MBBS, PhD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-02
Primary Completion
2016-08-27
Completion
2017-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01720264 on ClinicalTrials.gov